deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02318277

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Sponsor: AstraZeneca

Conditions Head and Neck Cancer Lung Cancer Solid Tumors UC (Urothelial Cancer)
Interventions INCB024360 MEDI4736
Updated 14 times since 2017 Last updated: Jan 7, 2022 Started: Jan 5, 2015 Primary completion: Aug 28, 2019 Completion: Oct 16, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Head and Neck Cancer and Lung Cancer and is currently completed. AstraZeneca leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Feb 2018 · 5 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Feb 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Completed → Active Not Recruiting

▶ Show 9 earlier versions

  1. Aug 2019 — Mar 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  2. May 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Nov 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2018 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chicago, United States , Dallas, United States , Denver, United States , Durham, United States , Houston, United States , Huntersville, United States , Louisville, United States , Miami, United States , Port Saint Lucie, United States , San Francisco, United States and 3 more locations